123 related articles for article (PubMed ID: 10750473)
1. Chronic viral hepatitis C: management update.
Gutfreund KS; Bain VG
CMAJ; 2000 Mar; 162(6):827-33. PubMed ID: 10750473
[TBL] [Abstract][Full Text] [Related]
2. Treatment of chronic hepatitis C in patients who failed interferon monotherapy: effects of higher doses of interferon and ribavirin combination therapy. The Virginia Cooperative Hepatitis Treatment Group.
Shiffman ML; Hofmann CM; Gabbay J; Luketic VA; Sterling RK; Sanyal AJ; Contos MJ; Ryan MJ; Yoshida C; Rustgi V
Am J Gastroenterol; 2000 Oct; 95(10):2928-35. PubMed ID: 11051370
[TBL] [Abstract][Full Text] [Related]
3. Interferon-alpha-2b + ribavirin for the treatment of chronic hepatitis C in non-responders to interferon-alpha-monotherapy.
Tromm A; Greving I; Griga T; Mankel K; Hüppe D
Z Gastroenterol; 2000 Feb; 38(2):159-64. PubMed ID: 10721171
[TBL] [Abstract][Full Text] [Related]
4. Sequential versus concomitant administration of ribavirin and interferon alfa-n3 in patients with chronic hepatitis C not responding to interferon alone: results of a randomized, controlled trial.
Sostegni R; Ghisetti V; Pittaluga F; Marchiaro G; Rocca G; Borghesio E; Rizzetto M; Saracco G
Hepatology; 1998 Aug; 28(2):341-6. PubMed ID: 9695995
[TBL] [Abstract][Full Text] [Related]
5. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group.
McHutchison JG; Gordon SC; Schiff ER; Shiffman ML; Lee WM; Rustgi VK; Goodman ZD; Ling MH; Cort S; Albrecht JK
N Engl J Med; 1998 Nov; 339(21):1485-92. PubMed ID: 9819446
[TBL] [Abstract][Full Text] [Related]
6. Maintenance therapy with ribavirin in patients with chronic hepatitis C who fail to respond to combination therapy with interferon alfa and ribavirin.
Hoofnagle JH; Ghany MG; Kleiner DE; Doo E; Heller T; Promrat K; Ong J; Khokhar F; Soza A; Herion D; Park Y; Everhart JE; Liang TJ
Hepatology; 2003 Jul; 38(1):66-74. PubMed ID: 12829988
[TBL] [Abstract][Full Text] [Related]
7. A dose-ranging study of pegylated interferon alfa-2b and ribavirin in chronic hepatitis C. The Hepatitis C Intervention Therapy Group.
Glue P; Rouzier-Panis R; Raffanel C; Sabo R; Gupta SK; Salfi M; Jacobs S; Clement RP
Hepatology; 2000 Sep; 32(3):647-53. PubMed ID: 10960463
[TBL] [Abstract][Full Text] [Related]
8. New proposal for response-guided peg-interferon-plus-ribavirin combination therapy for chronic hepatitis C virus genotype 2 infection.
Abe H; Aida Y; Ishiguro H; Yoshizawa K; Seki N; Miyazaki T; Itagaki M; Sutoh S; Ika M; Kato K; Shimada N; Tsubota A; Aizawa Y
J Med Virol; 2013 Sep; 85(9):1523-33. PubMed ID: 23775277
[TBL] [Abstract][Full Text] [Related]
9. Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. International Hepatitis Interventional Therapy Group.
Davis GL; Esteban-Mur R; Rustgi V; Hoefs J; Gordon SC; Trepo C; Shiffman ML; Zeuzem S; Craxi A; Ling MH; Albrecht J
N Engl J Med; 1998 Nov; 339(21):1493-9. PubMed ID: 9819447
[TBL] [Abstract][Full Text] [Related]
10. Interferon-antibodies and the breakthrough phenomenon during ribavirin/interferon-alpha combination therapy and interferon-alpha monotherapy of patients with chronic hepatitis C.
Hoffmann RM; Berg T; Teuber G; Prümmer O; Leifeld L; Jung MC; Spengler U; Zeuzem S; Hopf U; Pape GR
Z Gastroenterol; 1999 Aug; 37(8):715-23. PubMed ID: 10494606
[TBL] [Abstract][Full Text] [Related]
11. Safety of combination interferon alfa-2b/ribavirin therapy in chronic hepatitis C-relapsed and treatment-naive patients.
Maddrey WC
Semin Liver Dis; 1999; 19 Suppl 1():67-75. PubMed ID: 10349694
[TBL] [Abstract][Full Text] [Related]
12. A small percentage of patients with hepatitis C receive triple therapy with boceprevir or telaprevir.
Chen EY; Sclair SN; Czul F; Apica B; Dubin P; Martin P; Lee WM
Clin Gastroenterol Hepatol; 2013 Aug; 11(8):1014-20.e1-2. PubMed ID: 23602817
[TBL] [Abstract][Full Text] [Related]
13. [Effectiveness of antiviral treatment of patients with chronic hepatitis C (a Polish multicenter study)].
Juszczyk J; Bolewska B; Flieger J; Swietek K; Adamek B; Biskupska-Karasińska M; Dziambor AP; Boroń-Kaczmarska A; Wawrzynowicz-Syczewska M; Cianciara J; Kozłowska J; Daniluk J; Słomka M; Dudziak M; Zaborowski P; Gładysz A; Piszko P; Gonciarz Z; Mazur W; Machniak M; Kryczka W; Zarebska-Michaluk D; Trocha H; Witczak-Malinowska K; Lakomy E; Kuydowicz J; Niwicka-Michałowska A
Pol Merkur Lekarski; 2001 Oct; 11(64):340-3. PubMed ID: 11770315
[TBL] [Abstract][Full Text] [Related]
14. Interferon-alpha-2B and ribavirin in combination for chronic hepatitis C patients not responding to interferon-alpha alone: an Italian multicenter, randomized, controlled, clinical study.
Barbaro G; Di Lorenzo G; Soldini M; Giancaspro G; Bellomo G; Belloni G; Grisorio B; Annese M; Bacca D; Francavilla R; Rizzo G; Barbarini G
Am J Gastroenterol; 1998 Dec; 93(12):2445-51. PubMed ID: 9860407
[TBL] [Abstract][Full Text] [Related]
15. Cutaneous reactions to interferon and ribavirin.
Chamberlain AJ; Poon E
Intern Med J; 2004 Aug; 34(8):519. PubMed ID: 15317557
[No Abstract] [Full Text] [Related]
16. [Vogt-Koyanagi-Harada disease associated with interferon-alpha and ribavirin therapy for chronic hepatitis C infection].
Chebil A; Kort F; Bouraoui R; Youssef NB; El Matri L
J Fr Ophtalmol; 2010 Mar; 33(3):185-8. PubMed ID: 20172621
[TBL] [Abstract][Full Text] [Related]
17. Paternal use of ribavirin-interferon alpha 2B combination therapy before conception.
Taguchi N; Ito S
Can Fam Physician; 2005 Dec; 51(12):1623-5. PubMed ID: 16805078
[TBL] [Abstract][Full Text] [Related]
18. The uncertain natural history of thyrotoxic patients treated with combination interferon alfa-2beta and ribavirin.
Tran HA
Arch Intern Med; 2005 May; 165(9):1072; author reply 1072-3. PubMed ID: 15883255
[No Abstract] [Full Text] [Related]
19. Leucopenia is a side effect of combination therapy for hepatitis C infection.
Russo F; Bacosi M; Miglioresi L; Ricci GL
Am J Gastroenterol; 2000 Apr; 95(4):1100-1. PubMed ID: 10763981
[No Abstract] [Full Text] [Related]
20. Male periconceptional ribavir-ininterferon alpha-2b exposure with no adverse fetal effects.
Bianca S; Ettore G
Birth Defects Res A Clin Mol Teratol; 2003 Jan; 67(1):77-8. PubMed ID: 12749388
[No Abstract] [Full Text] [Related]
[Next] [New Search]
